Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer

1 Nov 2019

Abstract excerpt

Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31747605
DOI: 10.1016/j.celrep.2019.10.068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerPMID 31747605Read ↗

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapiesSemantic proximity Read ↗

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapiesSemantic proximity Read ↗

MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP InhibitorsSemantic proximity Read ↗

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrenceSemantic proximity Read ↗

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistanceSemantic proximity Read ↗

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7Semantic proximity Read ↗

Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.Semantic proximity Read ↗

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistanceSemantic proximity Read ↗

EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cellsSemantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.